Raymond James Financial Services Advisors Inc. Reduces Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Raymond James Financial Services Advisors Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 46.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,347 shares of the biopharmaceutical company’s stock after selling 5,532 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,270,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Allworth Financial LP increased its position in shares of Alnylam Pharmaceuticals by 708.7% in the 3rd quarter. Allworth Financial LP now owns 186 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 163 shares during the period. SeaCrest Wealth Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at about $44,000. SCHRODERS IS Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $74,000. 1832 Asset Management L.P. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $88,000. Finally, Trust Co. of Vermont purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $100,000.

Analyst Ratings Changes

A number of equities analysts have issued reports on ALNY shares. HC Wainwright reduced their price target on shares of Alnylam Pharmaceuticals from $430.00 to $415.00 and set a “buy” rating for the company in a research report on Wednesday, November 2nd. Piper Sandler raised their target price on shares of Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the stock an “overweight” rating in a report on Friday, December 16th. StockNews.com started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, October 28th. Finally, JPMorgan Chase & Co. lowered their target price on Alnylam Pharmaceuticals from $204.00 to $200.00 and set a “neutral” rating on the stock in a research note on Monday, October 24th. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $239.95.

Alnylam Pharmaceuticals Stock Down 1.4 %

Shares of NASDAQ ALNY opened at $228.56 on Friday. The company has a quick ratio of 3.33, a current ratio of 3.48 and a debt-to-equity ratio of 3.85. Alnylam Pharmaceuticals, Inc. has a 52-week low of $117.58 and a 52-week high of $242.97. The firm has a market cap of $28.12 billion, a price-to-earnings ratio of -23.39 and a beta of 0.50. The company’s 50-day simple moving average is $226.38 and its 200-day simple moving average is $204.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($1.46). Alnylam Pharmaceuticals had a negative return on equity of 430.74% and a negative net margin of 123.02%. The firm had revenue of $264.31 million during the quarter, compared to analyst estimates of $291.81 million. During the same period in the prior year, the firm earned ($1.72) earnings per share. The business’s revenue was up 40.9% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -9.64 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.